253 related articles for article (PubMed ID: 14687421)
1. Problems and solutions in calculating quality-adjusted life years (QALYs).
Prieto L; Sacristán JA
Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
3. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
Roe RH; Lass JH; Brown GC; Brown MM
Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
[TBL] [Abstract][Full Text] [Related]
4. Effect of health-related quality-of-life instrument and quality-adjusted life year calculation method on the number of life years gained in the critical care setting.
Vainiola T; Roine RP; Pettilä V; Kantola T; Räsänen P; Sintonen H
Value Health; 2011 Dec; 14(8):1130-4. PubMed ID: 22152183
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of cataract surgery in the second eye.
Busbee BG; Brown MM; Brown GC; Sharma S
Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
[TBL] [Abstract][Full Text] [Related]
6. Not all "quality-adjusted life years" are equal.
Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
[TBL] [Abstract][Full Text] [Related]
7. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
8. [QALYS or not QALYS: that is the question?].
Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
[TBL] [Abstract][Full Text] [Related]
9. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
Gupta OP; Brown GC; Brown MM
Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of multilevel hemilaminectomy for lumbar stenosis-associated radiculopathy.
Parker SL; Fulchiero EC; Davis BJ; Adogwa O; Aaronson OS; Cheng JS; Devin CJ; McGirt MJ
Spine J; 2011 Aug; 11(8):705-11. PubMed ID: 21641874
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of single-level instrumented posterolateral lumbar fusion at 5 years after surgery.
Glassman SD; Polly DW; Dimar JR; Carreon LY
Spine (Phila Pa 1976); 2012 Apr; 37(9):769-74. PubMed ID: 20489676
[TBL] [Abstract][Full Text] [Related]
13. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
[TBL] [Abstract][Full Text] [Related]
14. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
[TBL] [Abstract][Full Text] [Related]
15. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
16. Capabilities as menus: a non-welfarist basis for QALY evaluation.
Bleichrodt H; Quiggin J
J Health Econ; 2013 Jan; 32(1):128-37. PubMed ID: 23202258
[TBL] [Abstract][Full Text] [Related]
17. Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score.
Åberg F; Mäklin S; Räsänen P; Roine RP; Sintonen H; Koivusalo AM; Höckerstedt K; Isoniemi H
Liver Transpl; 2011 Nov; 17(11):1333-43. PubMed ID: 21770017
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
19. A utility-theoretic model for QALYs and willingness to pay.
Klose T
Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
[TBL] [Abstract][Full Text] [Related]
20. Global cost-effectiveness of cataract surgery.
Lansingh VC; Carter MJ; Martens M
Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
